Literature DB >> 20848907

Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds.

S O Bachurin1, A A Ustyugov, O Peters, T A Shelkovnikova, V L Buchman, N N Ninkina.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20848907     DOI： 10.1134/s1607672909050032

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


× No keyword cloud information.
  10 in total

Review 1.  Emerging prospects for the disease-modifying treatment of Alzheimer's disease.

Authors:  Lary C Walker; Chris C Ibegbu; Charles W Todd; Harriet L Robinson; Mathias Jucker; Harry LeVine; Sam Gandy
Journal:  Biochem Pharmacol       Date:  2005-04-01       Impact factor: 5.858

Review 2.  Alzheimer's disease: progress in the development of anti-amyloid disease-modifying therapies.

Authors:  Daniel D Christensen
Journal:  CNS Spectr       Date:  2007-02       Impact factor: 3.790

3.  Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer.

Authors:  S Bachurin; E Bukatina; N Lermontova; S Tkachenko; A Afanasiev; V Grigoriev; I Grigorieva; Y Ivanov; S Sablin; N Zefirov
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

4.  [Action of dimebon on histamine receptors].

Authors:  I A Matveeva
Journal:  Farmakol Toksikol       Date:  1983 Jul-Aug

5.  A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.

Authors:  Gilbert Gallardo; Oliver M Schlüter; Thomas C Südhof
Journal:  Nat Neurosci       Date:  2008-02-24       Impact factor: 24.884

6.  Developmental loss and resistance to MPTP toxicity of dopaminergic neurones in substantia nigra pars compacta of gamma-synuclein, alpha-synuclein and double alpha/gamma-synuclein null mutant mice.

Authors:  Darren C Robertson; Oliver Schmidt; Natalia Ninkina; Paul A Jones; John Sharkey; Vladimir L Buchman
Journal:  J Neurochem       Date:  2004-06       Impact factor: 5.372

Review 7.  Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease.

Authors:  J Steven Jacobsen; Peter Reinhart; Menelas N Pangalos
Journal:  NeuroRx       Date:  2005-10

8.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.

Authors:  Rachelle S Doody; Svetlana I Gavrilova; Mary Sano; Ronald G Thomas; Paul S Aisen; Sergey O Bachurin; Lynn Seely; David Hung
Journal:  Lancet       Date:  2008-07-19       Impact factor: 79.321

9.  Neurons expressing the highest levels of gamma-synuclein are unaffected by targeted inactivation of the gene.

Authors:  Natalia Ninkina; Katerina Papachroni; Darren C Robertson; Oliver Schmidt; Liz Delaney; Francis O'Neill; Felipe Court; Arnon Rosenthal; Susan M Fleetwood-Walker; Alun M Davies; Vladimir L Buchman
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

Review 10.  Cell systems and the toxic mechanism(s) of alpha-synuclein.

Authors:  Mark R Cookson; Marcel van der Brug
Journal:  Exp Neurol       Date:  2007-06-04       Impact factor: 5.330
  10 in total
  9 in total

1.  Testing the amyloid hypothesis of Alzheimer's disease in vivo.

Authors:  Sam Gandy
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

2.  FUS gene mutations associated with familiar forms of amyotrophic lateral sclerosis affect cellular localization and aggregation properties of the encoded protein.

Authors:  T A Shelkovnikova; A A Ustyugov; A P Smirnov; V I Skvortsova; V L Buchman; S O Bachurin; N N Ninkina
Journal:  Dokl Biochem Biophys       Date:  2011-07-03       Impact factor: 0.788

3.  Gamma-carboline inhibits neurodegenerative processes in a transgenic model of amyotrophic lateral sclerosis.

Authors:  E V Bronovitsky; A V Deikin; T G Ermolkevich; A B Elyakov; E N Fedorov; E R Sadchikova; I L Goldman; R K Ovchinnikov; A Yu Roman; I V Khritankova; M S Kukharsky; V L Buchman; S O Bachurin; A A Ustyugov
Journal:  Dokl Biochem Biophys       Date:  2015-07-12       Impact factor: 0.788

4.  Dimebon activates autophagosome components in human neuroblastoma SH-SY5Y cells.

Authors:  I V Khritankova; M S Kukharskiy; O A Lytkina; S O Bachurin; B Y Shorning
Journal:  Dokl Biochem Biophys       Date:  2012-11-07       Impact factor: 0.788

Review 5.  Novel Sites of Neuroprotective Action of Dimebon (Latrepirdine).

Authors:  Aleksey Ustyugov; Elena Shevtsova; Sergey Bachurin
Journal:  Mol Neurobiol       Date:  2015-06-30       Impact factor: 5.590

6.  Latrepirdine (dimebon) enhances autophagy and reduces intracellular GFP-Aβ42 levels in yeast.

Authors:  Prashant R Bharadwaj; Giuseppe Verdile; Renae K Barr; Veer Gupta; John W Steele; M Lenard Lachenmayer; Zhenyu Yue; Michelle E Ehrlich; Gregory Petsko; Shulin Ju; Dagmar Ringe; Sonia E Sankovich; Joanne M Caine; Ian G Macreadie; Sam Gandy; Ralph N Martins
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

7.  Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice.

Authors:  Tatyana A Shelkovnikova; Alexey A Ustyugov; Steven Millership; Owen Peters; Oleg Anichtchik; Maria Grazia Spillantini; Vladimir L Buchman; Sergey O Bachurin; Natalia N Ninkina
Journal:  Neurodegener Dis       Date:  2011-05-12       Impact factor: 2.977

8.  Gamma-Carbolines Derivatives As Promising Agents for the Development of Pathogenic Therapy for Proteinopathy.

Authors:  V I Skvortsova; S O Bachurin; A A Ustyugov; M S Kukharsky; A V Deikin; V L Buchman; N N Ninkina
Journal:  Acta Naturae       Date:  2018 Oct-Dec       Impact factor: 1.845

Review 9.  Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases.

Authors:  P R Bharadwaj; K A Bates; T Porter; E Teimouri; G Perry; J W Steele; S Gandy; D Groth; R N Martins; Giuseppe Verdile
Journal:  Transl Psychiatry       Date:  2013-12-03       Impact factor: 6.222
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.